[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"allogeneic-hematopoietic-stem-cell-transplantation-hsct\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:allogeneic-hematopoietic-stem-cell-transplantation-hsct":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,68,95,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100523298","early-detection-of-infectious-and-noninfectious-lung-diseases-following-allogeneic-hematopoietic-stem-cell-transplantation-100523298",false,"NCT06093867","Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation","A Prospective Approach for the Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Stated willingness to comply with all study procedures and availability for the duration of the study.\n2. Male or female, aged 5 - 70 years of age\n3. Are to be treated with allogeneic HSCT for a hematologic malignancy, blood, or immune system disorders at the NIH Clinical Center.\n4. Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1\\. Pregnancy or lactation\n\na. HSCT is not available to pregnant women or lactating women in the intramural program. For women of reproductive potential, have a negative serum pregnancy test during the screening period. Women of reproductive potential are defined as sexually mature women who have not undergone a hysterectomy, bilateral oophorectomy, or tubal occlusion; or who have not been naturally postmenopausal (i.e., who have not menstruated at all for at least the preceding 1 year prior to signing informed consent unrelated to hormonal contraception).","ALL","5 Years","70 Years",{"count":20,"type":21},40,"ESTIMATED","OBSERVATIONAL","Background:\n\nStem cell transplants (called hematopoietic stem cell transplantation, or HSCT) are used to treat various diseases. But when the cells for this procedure are donated by someone other than the person who receives the HSCT ( allogeneic HSCT ), the recipient has an increased risk of lung inflammation and scarring. This happens when their immune cells attack healthy lung cells. In this natural history study, researchers will look for the best ways to detect developing lung inflammations earlier after an HSCT.\n\nObjective:\n\nTo see if certain tests can detect early signs of lung inflammation in people after HSCT.\n\nEligibility:\n\nPeople aged 5 to 70 years who will have HSCT as part of another NIH study.\n\nDesign:\n\nParticipants will undergo these tests prior to their HSCT. These tests will then be repeated regularly for 2 years:\n\nUltra-low dose computed tomography (CT) scans. Participants will lie on a table that slides through a machine; the machine uses X-rays to get pictures of the inside of the body. This type of scan uses less radiation than normal CT scans.\n\nBronchoscopy with lavage: Participants will be sedated. A flexible tube will be inserted through the mouth and into the airways. Salt water will be squirted into the lung, then sucked out to collect cells and fluids from the lung. Another tube with a camera may be inserted into the airways to take pictures.\n\nBlood tests. Blood will be drawn every 2 to 4 weeks.\n\nPulmonary function tests. Participants will breathe into a machine to test their lung function. They will see how far they can walk in 6 minutes.",[25],"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)",[27,28],"allogeneic hematopoietic stem cell transplantation (HSCT)","early detection of inflammatory injury","RECRUITING","2026-06-18",{"date":32,"type":33},"2026-06-22","ACTUAL",{"date":35,"type":33},"2024-04-08",{"date":37,"type":21},"2029-10-01",{"name":39,"class":40},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":41},"100636697","longitudinal-cohort-study-on-invasive-fungal-disease-after-allogeneic-hematopoietic-stem-cell-transplantation-100636697","NCT07569055","Longitudinal Cohort Study on Invasive Fungal Disease After Allogeneic Hematopoietic Stem Cell Transplantation","Retrospective and Prospective Longitudinal Observational Study on Invasive Fungal Disease After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\nSince January 1, 2014, patients who underwent allo-HSCT at Peking University People's Hospital and other assistance centers.\n\nExclusion Criteria:\n\n1. For any reason, such as the occurrence of severe mental disorders, the follow-up information may be unavailable;\n2. Patients deemed unsuitable for the study by the researchers.",{"count":50,"type":21},6000,"Invasive fungal disease (IFD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), characterized by high incidence and high mortality. According to the data from a multi-center study in China (CAESAR 2.0), even with the extensive use of antifungal active drugs for prevention, the cumulative incidence of IFD one year after HSCT still reached 6.3%, and the IFD-related mortality rate was 48.28%. In recent years, with the improvement of transplantation techniques, the application of new antifungal drugs and the optimization of diagnostic methods, the pathogen spectrum and clinical characteristics of IFD have undergone significant changes. Compared with ten years ago, the proportion of non-Aspergillus pathogens (such as Candida and Mucophora) has significantly increased, while the proportion of Aspergillus has relatively decreased. In addition, different types of invasive mycosis (such as invasive aspergillosis and invasive fusarium) show significant differences in clinical manifestations, onset time and prognosis. However, at present, large-scale prospective cohort studies on IFD after HSCT in China are still relatively scarce, and the diagnosis and treatment norms and prevention strategies in clinical practice still need to be further optimized. This study intends to conduct a multi-center retrospective and prospective combined longitudinal cohort study to comprehensively register the basic information, diagnosis, treatment and prognosis of IFD patients after HSCT, providing evidence-based medical basis for establishing new clinical diagnosis and treatment technologies and improving the long-term survival rate of patients.",[53,25],"Invasive Fungal Disease",[55,53,56,57],"Allogeneic Hematopoietic Stem Cell Transplantation","Prediction","Prognosis","2026-05-01",{"date":60,"type":33},"2026-05-06",{"date":62,"type":33},"2025-03-15",{"date":64,"type":21},"2031-03-14",{"name":66,"class":67},"Peking University People's Hospital","OTHER",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":41},"100600753","phase-4-ruxolitinib-decitabine-intensified-conditioning-regimen-for-aml-a-randomized-trial-100600753","NCT07101588","Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","Ruxolitinib and Decitabine-Enhanced Conditioning Versus Modified Bu\u002FCy or BuF Conditioning for the Impact on Relapse of Acute Myeloid Leukemia in First Complete Remission (CR1)After Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter, Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* 1\\) Acute myeloid leukemia with indications for allogeneic hematopoietic stem cell transplantation, CR1 2) Have HLA-matched sibling donors or haploidentical donors or ≥8\u002F10 HLA-matched unrelated donors 3) The patients' ages range from 12 to 64 years old 4) Liver function: ALT and AST≤2.5 times the upper limit of normal values, bilirubin ≤2 times the upper limit of normal values 5) Renal function: Creatinine ≤ the upper limit of the normal value 6) There are no uncontrollable infections or serious mental and psychological disorders 7) Sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Patients with acute promyelocytic leukemia (M3) 2. One of the donor and recipient is pregnant 3. Suffering from mental illness or other conditions that prevent one from following the plan.","14 Years","75 Years",{"count":78,"type":21},200,"INTERVENTIONAL",[81],"PHASE4","This study aims to determine whether the recurrence rate of high-risk acute myeloid leukemia CR1 patients who received allogeneic hematopoietic stem cell transplantation with the Ruxolitinib, Decitabine combined with Bu\u002FCy or BuF intensive pretreatment regimen is reduced compared with the traditional Bu\u002FCy or BuFpretreatment regimen.",[25],[85],"HSCT","2026-03-18",{"date":88,"type":33},"2026-03-20",{"date":90,"type":33},"2025-01-01",{"date":92,"type":21},"2028-12-30",{"name":94,"class":67},"Chinese PLA General Hospital",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":101,"maxAge":18,"enrollmentInfo":102,"targetDuration":4,"studyType":79,"phases":104,"briefSummary":106,"conditions":107,"keywords":110,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":41},"100595615","phase-ii-clinical-study-on-the-safety-and-efficacy-of-combined-car-t-therapy-following-autologous-stem-cell-transplantation-in-multiple-myeloma-100595615","NCT07034755","Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma","Inclusion Criteria:\n\n* Age: 18-70 years old\n* Expected survival: \\>12 weeks\n* Diagnosis: Multiple myeloma confirmed by physical examination, pathological examination, laboratory tests, and imaging studies\n* Post-chemotherapy status:\n* Patients who achieved partial response (PR) or better but failed to reach complete response (CR) after four cycles of first-line chemotherapy Patients who achieved CR after four cycles of first-line chemotherapy but have high-risk factors\n* Liver function:\n\n  * ALT and AST \\\u003C 3 times the upper limit of normal\n  * Bilirubin \\\u003C 2.0 mg\u002Fdl\n* Performance status: Karnofsky Performance Status (KPS) \\>50%\n* Organ function: No severe liver, kidney, or heart diseases\n* Stem cell transplantation: Eligible for stem cell transplantation\n* Venous access: Able to undergo venous blood sampling without contraindications to leukapheresis\n* Informed consent: Capable of understanding and voluntarily signing a written informed consent form\n\nExclusion Criteria:\n\n* Pregnancy or lactation, or women planning pregnancy within the next 6 months\n* Infectious diseases(e.g., HIV, active tuberculosis)\n* Active hepatitis B or C infection\n* Feasibility assessment showing lymphocyte-targeted transfection rate \\\u003C10% or insufficient expansion (\\\u003C5-fold) under CD3\u002FCD28 co-stimulation\n* Abnormal vital signs or inability to cooperate with examinations\n* Psychiatric\u002Fpsychological disorders precluding treatment compliance or efficacy evaluation\n* Severe allergic constitution or history of severe allergies, especially to IL-2\n* Systemic or localized severe infection requiring anti-infective therapy\n* Severe autoimmune diseases\n* Other conditions deemed unsuitable for inclusion by the investigator","18 Years",{"count":103,"type":21},20,[105],"NA","Chimeric Antigen Receptor T-Cell (CAR-T) immunotherapy is a rapidly developing novel approach in adoptive immunotherapy for tumors in recent years. Its main characteristic lies in genetically engineering T cells to express tumor antigen-specific receptors, thereby endowing them with targeting capability, cytotoxicity, and persistence. This approach has demonstrated remarkable efficacy in relapsed\u002Frefractory hematologic malignancies. Research on multiple myeloma (MM)-specific CAR-T cells has also been progressively conducted with promising outcomes, establishing CAR-T cell therapy as an effective new treatment strategy for MM. Notably, targets such as B-cell maturation antigen (BCMA) and GPRC5D have emerged as prominent therapeutic targets for CAR-T cell therapy.\n\nTherefore, we propose to evaluate the efficacy and safety of sequential CAR-T therapy following autologous hematopoietic stem cell transplantation (ASCT) in newly diagnosed MM patients who achieve partial response (PR) or better after four cycles of first-line chemotherapy but fail to attain complete response (CR), or those who achieve CR but present with high-risk factors. The clinical data from this study will provide evidence-based support for novel treatment strategies in this subset of MM patients.",[108,25,109],"Multiple Myeloma (MM)","Chimeric Antigen Receptor T-cell",[111,112,113],"Chimeric Antigen Receptor T-Cell","allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","multiple myeloma (MM)","NOT_YET_RECRUITING","2025-06-29",{"date":117,"type":33},"2025-07-02",{"date":119,"type":21},"2025-07-01",{"date":121,"type":21},"2028-04-01",{"name":123,"class":67},"The Affiliated Hospital of Xuzhou Medical University",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":101,"maxAge":76,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":132,"conditions":133,"keywords":134,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":41},"100164968","pharmacokinetics-of-posaconazole-in-allogeneic-transplant-patients-with-mucositis-100164968","NCT01420562","Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis","Inclusion Criteria:\n\n* Patients receiving allogeneic stem cell transplantation - Treated with prophylactic posaconazole: oral suspension (200mg three times daily) or tablet (300mg once daily) to prevent invasive fungal infections\n\nExclusion Criteria:\n\n* Gastroparesis\n* Vomiting or diarrhea within 2 hours after intake of posaconazole\n* Concomitant administration of potent inducers of the enzyme UGT1A4: carbamazepine,phenytoin, phenobarbital, rifabutin, rifampicin,...\n* Age under 18 years",{"count":131,"type":21},55,"The goal of this study is to calculate pharmacokinetic parameters and to evaluate the trough levels of posaconazole reached in patients with different stages of mucositis, due to chemotherapy and total body irradiation.",[25],[135,136,137,138,139],"allogeneic HSCT","posaconazole","prophylaxis","mucositis","pharmacokinetics","2024-07-12",{"date":142,"type":33},"2024-07-15",{"date":144,"type":4},"2011-09",{"date":146,"type":21},"2025-03",{"name":148,"class":67},"Universitaire Ziekenhuizen KU Leuven"]